4.7 Editorial Material

Transcriptomic drug-response gene signatures are informative for the stratification of patients for clinical trials

Related references

Note: Only part of the references are listed.
Article Allergy

Mapping atopic dermatitis and anti-IL-22 response signatures to type 2-low severe neutrophilic asthma

Yusef Eamon Badi et al.

Summary: The disease signature identified in atopic dermatitis (AD) can also be seen in adults with severe asthma, and the transcriptomic signature of AD patients who respond to anti-IL-22 therapy is enriched in severe asthma. The AD disease signature is enriched in the blood and sputum of patients with asthma and is correlated with the severity of asthma. The FZ-response signature is enriched in the blood and sputum of asthmatic patients and is correlated with the presence of neutrophils and mixed granulocytes in the sputum.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

Article Allergy

IL-22 promotes allergic airway inflammation in epicutaneously sensitized mice

Juan Manuel Leyva-Castillo et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)

Review Medicine, General & Internal

Asthma Endotypes and an Overview of Targeted Therapy for Asthma

Sarah Svenningsen et al.

FRONTIERS IN MEDICINE (2017)

Article Critical Care Medicine

Dual Role of IL-22 in Allergic Airway Inflammation and its Cross-talk with IL-17A

Anne-Gaelle Besnard et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)

Article Critical Care Medicine

T-helper Type 2-driven Inflammation Defines Major Subphenotypes of Asthma

Prescott G. Woodruff et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)

Article Critical Care Medicine

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma

Patrick Flood-Page et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)